Stockscreener 앱 받기
25.51
1.71%
0.43
시장 영업 전:
26.48
0.97
+3.80%
전일 마감가:
$25.08
열려 있는:
$24.89
하루 거래량:
375.45K
Relative Volume:
3.94
시가총액:
$1.19B
수익:
-
순이익/손실:
-
주가수익비율:
-31.36
EPS:
-0.8135
순현금흐름:
-
1주 성능:
-5.52%
1개월 성능:
-9.12%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$23.81
$25.96
1주일 범위
$23.81
$27.95
52주 변동 폭
$23.00
$32.00
Hemab Therapeutics Holdings Inc Stock (COAG) Company Profile
명칭
Hemab Therapeutics Holdings Inc
전화
45 2138 7627
주소
101 MAIN STREET, CAMBRIDGE
Compare COAG vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
COAG
Hemab Therapeutics Holdings Inc
|
25.51 | 1.17B | 0 | 0 | 0 | -0.8135 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Hemab Therapeutics Holdings Inc 주식(COAG)의 최신 뉴스
Hemab soars 89% on debut as biopharma IPOs stay strong in May - BioWorld News
Hemab Therapeutics Holdings, Inc.Common Stock (COAG) Stock Price, News, Quote & History - FinancialContent
Hemab Therapeutics Details Post-IPO Pipeline Push, Sutacimig Phase III Plans - Yahoo Finance
Jefferies Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Maintains Target Price $39 - Moomoo
SEPN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
MRVI Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
COAG: Lead asset moves to phase III, with robust pipeline and funding secured through 2029 - TradingView
Top Hemab Therapeutics (COAG) Competitors 2026 - MarketBeat
Hemab Therapeutics Pulls Back After 53% IPO Surge - Bez Kabli
Novo Holdings portfolio company Hemab Therapeutics completes successful Nasdaq IPO - Novo Holdings
Hemab Therapeutics Hldgs (COAG) Stock Analysis Report | Financials & Insights - Benzinga
Hemab Therapeutics (COAG) Stock Forecast and Price Target 2026 - MarketBeat
Hemab Therapeutics (COAG) Stock Trends and Sentiment 2026 - MarketBeat
Hemab Therapeutics (COAG) Earnings Date and Reports 2026 - MarketBeat
COAG Technical Analysis & ETF Price Forecast - Intellectia AI
Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - The Manila Times
Latest COAG ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Hemab Therapeutics Hldgs Initiated at Outperform by Evercore ISI Group - Moomoo
COAG Initiates Coverage By Evercore ISI Group -- Rating Upgraded to Outperform - GuruFocus
COAG Initiates Coverage by Goldman Sachs -- Price Target Announced at $36 - GuruFocus
Wedbush Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $42 - Moomoo
Hemab Therapeutics Hldgs Initiated at Buy by Jefferies - Moomoo
Hemab Therapeutics Hldgs Price Target Announced at $50.00/Share by Evercore ISI Group - Moomoo
Jefferies Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $39 - Moomoo
Evercore Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $50 - Moomoo
This Avalyn Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Goldman Sachs Initiates Coverage on Hemab Therapeutics With Buy Rating, $36 Price Target - marketscreener.com
Goldman Sachs Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $36 - Moomoo
Goldman Sachs initiates Hemab Therapeutics stock with buy rating on rare disease drug potential - Investing.com
ETFs Investing in Hemab Therapeutics Holdings, Inc. Stocks - TradingView
COAG Technical Analysis | Trend, Signals & Chart Patterns | HEMAB THERAPEUTICS HOLDINGS (NASDAQ:COAG) - ChartMill
Earnings Scheduled For May 21, 2026 - Sahm
Novo-backed biotech Hemab raises $301.5 million in upsized IPO - MSN
COAG SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Hemab Therapeutics Holdings, Inc. Q1 2026: Net loss $(22.7)M, EPS $(23.98) — 10-Q Summary - TradingView
Hemab Therapeutics Reports Q1 2026 Financial Results, Completes $346.7M IPO and Advances Breakthrough Therapy Sutacimig for Rare Bleeding Disorders - Minichart
Earnings Flash (COAG) Hemab Therapeutics Posts Q1 Net Loss $23.98 a Share - marketscreener.com
Hemab Therapeutics reports Q1 2026 net loss $22.7M, cash $163.5M; completed $346.7M IPO - TradingView
COAG: IPO raised $346.7M, advancing late-stage trials for rare bleeding disorder therapies - TradingView
Hemab Therapeutics (COAG) Q1 2026 loss, $346.7M IPO and FDA breakthrough nod - Stock Titan
FDA grants Hemab breakthrough tag on rare bleed drug as $346.7M IPO closes - Stock Titan
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) AI-Powered Stock Analysis - Meyka
Why Is Hemab Therapeutics Holdings, Inc. Common Stock (COAG) Stock Up Today? - Meyka
Why Is Hemab Therapeutics Holdings, Inc. Common Stock (COAG) Stock Down Today? - Meyka
Seaport, Hemab price upsized IPOs, eyeing $550M in proceeds - MSN
COAG SEC FilingsHEMAB THERAPEUTICS HOLDINGS 10-K, 10-Q, 8-K Forms - Stock Titan
Hemab Therapeutics Holdings Earnings Date, Reports & Earnings Call - Moomoo
Hemab Therapeutics Holdings Inc (COAG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Hemab Therapeutics Holdings Inc 주식 (COAG) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
May 20 '26 |
Buy |
24.94 |
996 |
24,840 |
6,376,968 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
May 12 '26 |
Buy |
24.90 |
6,387 |
159,036 |
6,372,170 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
May 11 '26 |
Buy |
24.81 |
39,869 |
989,226 |
6,365,783 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
May 07 '26 |
Buy |
24.46 |
9,906 |
242,323 |
6,324,431 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
May 08 '26 |
Buy |
24.98 |
1,483 |
37,045 |
6,325,914 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
May 04 '26 |
Buy |
18.00 |
2,675,000 |
48,150,000 |
6,149,096 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
May 05 '26 |
Buy |
24.63 |
97,411 |
2,399,546 |
6,246,507 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
May 06 '26 |
Buy |
24.60 |
68,018 |
1,673,399 |
6,314,525 |
1.27%
1.43%
자본화:
|
볼륨(24시간):